{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T18:41:22Z","timestamp":1793040082984,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T00:00:00Z","timestamp":1706572800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s12325-023-02757-x","type":"journal-article","created":{"date-parts":[[2024,1,30]],"date-time":"2024-01-30T02:04:41Z","timestamp":1706580281000},"page":"1184-1200","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Evolocumab-Based LDL-C Management in High and Very High Cardiovascular Risk Patients in German Clinical Practice: The HEYMANS Study"],"prefix":"10.1007","volume":"41","clinical-trial-number":[{"clinical-trial-number":"nct02770131","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2484-8068","authenticated-orcid":false,"given":"Michael","family":"Lehrke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Vogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6193-6377","authenticated-orcid":false,"given":"Volker","family":"Schettler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2823-0847","authenticated-orcid":false,"given":"Matthias","family":"Girndt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6588-0318","authenticated-orcid":false,"given":"Uwe","family":"Fraass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Tabbert-Zitzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3317-3528","authenticated-orcid":false,"given":"Ian","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7368-3306","authenticated-orcid":false,"given":"Nafeesa N.","family":"Dhalwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0508-0954","authenticated-orcid":false,"given":"Kausik K.","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,1,30]]},"reference":[{"key":"2757_CR1","unstructured":"World Health Organisation. Cardiovascular diseases (CVDs). 2021. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/cardiovascular-diseases-(cvds). Accessed 23 June 2022."},{"issue":"25","key":"2757_CR2","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1016\/j.jacc.2020.11.010","volume":"76","author":"GA Roth","year":"2020","unstructured":"Roth GA, Mensah GA, Johnson CO, et al. Global burden of cardiovascular diseases and risk factors, 1990\u20132019: update from the GBD 2019 study. J Am Coll Cardiol. 2020;76(25):2982\u20133021. https:\/\/doi.org\/10.1016\/j.jacc.2020.11.010.","journal-title":"J Am Coll Cardiol"},{"key":"2757_CR3","unstructured":"Statistisches Bundesamt Deutschland. Todesursachen in Deutschland. 2022. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Todesursachen\/Tabellen\/sterbefaelle-herz-kreislauf-erkrankungen-insgesamt.html. Accessed 20 Mar 2023."},{"key":"2757_CR4","unstructured":"Gesundheitsberichterstattung des Bundes. Sterbef\u00e4lle (absolut, Sterbeziffer, R\u00e4nge, Anteile) f\u00fcr die 10\/20\/50\/100\u00a0h\u00e4ufigsten Todesursachen (ab 1998). Gliederungsmerkmale: Jahre, Region, Alter, Geschlecht, ICD-10. 2023. https:\/\/www.gbe-bund.de\/gbe\/pkg_isgbe5.prc_menu_olap?p_uid=gastd&p_aid=79977881&p_sprache=D&p_help=0&p_indnr=516&p_indsp=4065&p_ityp=H&p_fid=. Accessed 20 Mar 2023."},{"issue":"1","key":"2757_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","volume":"41","author":"F Mach","year":"2020","unstructured":"Mach F, Baigent C, Catapano AL, et al. 2019 ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111\u201388. https:\/\/doi.org\/10.1093\/eurheartj\/ehz455.","journal-title":"Eur Heart J"},{"key":"2757_CR6","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.athplu.2022.07.024","volume":"50","author":"I Gouni-Berthold","year":"2022","unstructured":"Gouni-Berthold I, Schaper F, Schatz U, et al. Low-density lipoprotein cholesterol goal attainment in Germany: results from the DA VINCI study. Atheroscler Plus. 2022;50:10\u20136. https:\/\/doi.org\/10.1016\/j.athplu.2022.07.024.","journal-title":"Atheroscler Plus"},{"issue":"11","key":"2757_CR7","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/eurjpc\/zwaa047","volume":"28","author":"KK Ray","year":"2021","unstructured":"Ray KK, Molemans B, Schoonen WM, et al. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study. Eur J Prev Cardiol. 2021;28(11):1279\u201389. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa047.","journal-title":"Eur J Prev Cardiol"},{"issue":"34","key":"2757_CR8","doi-asserted-by":"publisher","first-page":"3227","DOI":"10.1093\/eurheartj\/ehab484","volume":"42","author":"FLJ Visseren","year":"2021","unstructured":"Visseren FLJ, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the task force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies with the special contribution of the European Association of Preventive Cardiology (EAPC). Eur Heart J. 2021;42(34):3227\u2013337. https:\/\/doi.org\/10.1093\/eurheartj\/ehab484.","journal-title":"Eur Heart J"},{"issue":"1","key":"2757_CR9","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.atherosclerosis.2011.06.028","volume":"217","author":"AL Catapano","year":"2011","unstructured":"Catapano AL, Reiner Z, De Backer G, et al. ESC\/EAS guidelines for the management of dyslipidaemias the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011;217(1):3\u201346. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2011.06.028.","journal-title":"Atherosclerosis"},{"issue":"39","key":"2757_CR10","doi-asserted-by":"publisher","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","volume":"37","author":"AL Catapano","year":"2016","unstructured":"Catapano AL, Graham I, De Backer G, et al. 2016 ESC\/EAS guidelines for the management of dyslipidaemias. Eur Heart J. 2016;37(39):2999\u20133058. https:\/\/doi.org\/10.1093\/eurheartj\/ehw272.","journal-title":"Eur Heart J"},{"issue":"2","key":"2757_CR11","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1007\/s12325-022-02357-1","volume":"40","author":"U Makhmudova","year":"2023","unstructured":"Makhmudova U, Wolf M, Willfeld K, Beier L, Weing\u00e4rtner O. Different perspectives of patients and physicians on LDL-C target achievement in the treatment of hypercholesterolemia: results on secondary prevention from the German PROCYON survey. Adv Ther. 2023;40(2):460\u201373. https:\/\/doi.org\/10.1007\/s12325-022-02357-1.","journal-title":"Adv Ther"},{"key":"2757_CR12","doi-asserted-by":"publisher","first-page":"100624","DOI":"10.1016\/j.lanepe.2023.100624","volume":"29","author":"KK Ray","year":"2023","unstructured":"Ray KK, Haq I, Bilitou A, et al. Treatment gaps in the implementation of LDL cholesterol control among high- and very high-risk patients in Europe between 2020 and 2021: the multinational observational SANTORINI study. Lancet Region Health Eur. 2023;29:100624. https:\/\/doi.org\/10.1016\/j.lanepe.2023.100624.","journal-title":"Lancet Region Health Eur"},{"issue":"6","key":"2757_CR13","doi-asserted-by":"publisher","first-page":"633","DOI":"10.21037\/cdt.2017.04.06","volume":"7","author":"K Kotseva","year":"2017","unstructured":"Kotseva K. The EUROASPIRE surveys: lessons learned in cardiovascular disease prevention. Cardiovasc Diagn Ther. 2017;7(6):633\u20139. https:\/\/doi.org\/10.21037\/cdt.2017.04.06.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"18","key":"2757_CR14","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.1177\/2047487318806359","volume":"25","author":"J Ferrieres","year":"2018","unstructured":"Ferrieres J, De Ferrari GM, Hermans MP, et al. Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: results from DYSIS II Europe. Eur J Prev Cardiol. 2018;25(18):1966\u201376. https:\/\/doi.org\/10.1177\/2047487318806359.","journal-title":"Eur J Prev Cardiol"},{"key":"2757_CR15","unstructured":"Gemeinsamer Bundesausschuss. Beschluss des Gemeinsamen Bundesausschusses \u00fcber eine \u00c4nderung der Arzneimittel-Richtlinie (AM-RL): Anlage III vom 28.02.2023: Nummer 35a, Nummer 35b und Nummer 35c\u2014Bempedoins\u00e4ure. 2023. https:\/\/www.g-ba.de\/beschluesse\/5774\/. Accessed 1 Mar 2023."},{"issue":"4","key":"2757_CR16","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1093\/ehjqcco\/qcac009","volume":"8","author":"KK Ray","year":"2022","unstructured":"Ray KK, Dhalwani N, Sibartie M, et al. Low-density lipoprotein cholesterol levels exceed the recommended European threshold for PCSK9i initiation: lessons from the HEYMANS study. Eur Heart J Qual Care Clin Outcomes. 2022;8(4):447\u201360. https:\/\/doi.org\/10.1093\/ehjqcco\/qcac009.","journal-title":"Eur Heart J Qual Care Clin Outcomes"},{"key":"2757_CR17","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.atherosclerosis.2023.01.002","volume":"366","author":"KK Ray","year":"2023","unstructured":"Ray KK, Bruckert E, Peronne-Filardi P, et al. Long-term persistence with evolocumab treatment and sustained reductions in LDL-cholesterol levels over 30\u00a0months: final results from the European observational HEYMANS study. Atherosclerosis. 2023;366:14\u201321. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2023.01.002.","journal-title":"Atherosclerosis"},{"issue":"15","key":"2757_CR18","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1161\/circulationaha.122.061620","volume":"146","author":"ML O'Donoghue","year":"2022","unstructured":"O\u2019Donoghue ML, Giugliano RP, Wiviott SD, et al. Long-term evolocumab in patients with established atherosclerotic cardiovascular disease. Circulation. 2022;146(15):1109\u201319. https:\/\/doi.org\/10.1161\/circulationaha.122.061620.","journal-title":"Circulation"},{"issue":"6","key":"2757_CR19","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1016\/j.cjco.2022.03.003","volume":"4","author":"M Gupta","year":"2022","unstructured":"Gupta M, Mancini GBJ, Wani RJ, et al. Real-world insights into evolocumab use in patients with hyperlipidemia: Canadian analysis from the ZERBINI study. CJC Open. 2022;4(6):558\u201367. https:\/\/doi.org\/10.1016\/j.cjco.2022.03.003.","journal-title":"CJC Open"},{"issue":"9","key":"2757_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1001\/jamacardio.2021.1810","volume":"6","author":"CP Cannon","year":"2021","unstructured":"Cannon CP, de Lemos JA, Rosenson RS, et al. Use of lipid-lowering therapies over 2 years in GOULD, a registry of patients with atherosclerotic cardiovascular disease in the US. JAMA Cardiol. 2021;6(9):1\u20139. https:\/\/doi.org\/10.1001\/jamacardio.2021.1810.","journal-title":"JAMA Cardiol"},{"key":"2757_CR21","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.ajmo.2023.100035","volume":"9","author":"J Eloso","year":"2023","unstructured":"Eloso J, Awad A, Zhao X, et al. PCSK9 inhibitor use and outcomes by concomitant lipid-lowering therapies in the veterans health administration. Am J Med Open. 2023;9:100035. https:\/\/doi.org\/10.1016\/j.ajmo.2023.100035.","journal-title":"Am J Med Open"},{"issue":"3","key":"2757_CR22","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.jacl.2022.03.004","volume":"16","author":"DR Donald","year":"2022","unstructured":"Donald DR, Reynolds VW, Hall N, DeClercq J, Choi L. Exploring rates of PCSK9 inhibitor persistence and reasons for treatment non-persistence in an integrated specialty pharmacy model. J Clin Lipidol. 2022;16(3):315\u201324. https:\/\/doi.org\/10.1016\/j.jacl.2022.03.004.","journal-title":"J Clin Lipidol"},{"issue":"5","key":"2757_CR23","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.jacl.2019.06.008","volume":"13","author":"CK Bradley","year":"2019","unstructured":"Bradley CK, Shrader P, Sanchez RJ, Peterson ED, Navar AM. The patient journey with proprotein convertase subtilisin\/kexin type\u00a09 inhibitors in community practice. J Clin Lipidol. 2019;13(5):725\u201334. https:\/\/doi.org\/10.1016\/j.jacl.2019.06.008.","journal-title":"J Clin Lipidol"},{"key":"2757_CR24","doi-asserted-by":"publisher","first-page":"7362551","DOI":"10.1155\/2023\/7362551","volume":"2023","author":"HD Choi","year":"2023","unstructured":"Choi HD, Kim JH. An updated meta-analysis for safety evaluation of alirocumab and evolocumab as PCSK9 inhibitors. Cardiovasc Ther. 2023;2023:7362551. https:\/\/doi.org\/10.1155\/2023\/7362551.","journal-title":"Cardiovasc Ther"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-023-02757-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-023-02757-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,20]],"date-time":"2024-02-20T18:14:56Z","timestamp":1708452896000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-023-02757-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,30]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["2757"],"URL":"https:\/\/doi.org\/10.1007\/s12325-023-02757-x","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,30]]},"assertion":[{"value":"27 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Michael Lehrke received grants and personal fees from Boehringer Ingelheim, MSD, Novo Nordisk and personal fees from Amgen, Sanofi, AstraZeneca, Bayer, Lilly, Daiichi Sankyo, Novarits. Volker Schettler declares to have received speaker\u2019s fees, travel support and\/or study grants from Amgen GmbH, Akcea GmbH, B.Braun Avitum AG, Daiichi Sankyo Deutschland GmbH, Fresenius Medical Care AG & Co. KGaA, KWHC Health Consulting GmbH, Novartis Pharma GmbH, Novo Nordisk GmbH, Sanofi-Aventis GmbH, Vifor Deutschland GmbH. Matthias Girndt declares speaker\u2019s and advisory fees from Amgen GmbH, Astellas GmbH, Bayer Vital GmbH, Daiichi Sankyo GmbH, Hexal AG, Novartis GmbH, Novo Nordisk GmbH, Pfizer GmbH, Sanofi GmbH, Vifor Fresenius GmbH. Anja Vogt declares speaker\u2019s and advisory fees from Aegerion, Amgen GmbH, Daiichi Sankyo GmbH, MSD GmbH, Novartis GmbH, Sanofi GmbH. Kausik K. Ray reports grants\/personal fees from Abbott, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Cargene, Daiichi Sankyo, Esperion, Kowa, Lilly, New Amsterdam Pharma, Novartis, Pfizer, Sanofi-Regeneron, Silence Therapeutics and Scribe Therapeutics. Ian Bridges is an employee of Amgen Ltd and stockholder of Amgen; Uwe Fraass and Anja Tabbert-Zitzler are employees of Amgen GmbH and stockholders of Amgen; Nafeesa N. Dhalwani is an employee of Amgen Inc. and stockholder of Amgen.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This study was conducted according to the Declaration of Helsinki and the guidelines of the International Council for Harmonization. The study was registered in ClinicalTrials.gov (Identifier NCT02770131). The study protocol and the protocol amendments were approved by the institutional ethics committees of each participating study center (Supplemental Table\u00a0S1); the ethics committee of the Bavarian state medical association acted as the lead ethics committee for the German sub-study of HEYMANS (study reference number 16030). All patients or their legally acceptable representatives provided written informed consent before participation in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}